Disposition of [14C]-LY2623091 Following Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs LY 2623091 (Primary)
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 01 Feb 2017 Results (n=294) assessing population pharmacokinetics of LY-2623091 using patients data from this and other four trials (NCT01427972, NCT02194465, NCT01237899), published in the Journal of Clinical Pharmacology
- 19 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.